Gilead Sciences (GILD) EPS (Basic) Growth (3y) (2012 - 2026)
Gilead Sciences (GILD) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -59.02% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 11.28% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 19.50% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -129.90% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -28.08% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -34.06% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -35.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -129.90% |
| Mar 31, 2026 | 27.32% |
| Dec 31, 2025 | 16.02% |
| Sep 30, 2025 | 19.94% |
| Jun 30, 2025 | 20.35% |
| Mar 31, 2025 | 379.69% |
| Dec 31, 2024 | 68.38% |
| Sep 30, 2024 | -21.27% |
| Jun 30, 2024 | 2.33% |
| Mar 31, 2024 | -64.36% |
| Dec 31, 2023 | -2.61% |
| Sep 30, 2023 | 83.59% |
| Jun 30, 2023 | 32.23% |
| Mar 31, 2023 | -13.51% |
| Dec 31, 2022 | 33.09% |
| Sep 30, 2022 | 52.46% |
| Jun 30, 2022 | -15.09% |
| Mar 31, 2022 | -81.63% |
| Dec 31, 2021 | -3.17% |
| Sep 30, 2021 | 8.33% |